Diabetes Devices Market

Diabetes Devices Market (Product Type: Glucose Monitoring Devices, Insulin Delivery Devices, Diabetes Management Software, and Artificial Pancreas System) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Diabetes Devises Market Outlook 2031

  • The global diabetes care devices market was valued at US$ 50.5 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.0% from 2022 to 2031
  • The global diabetes devices industry is anticipated to reach more than US$ 90.2 Bn by 2031

Analysts’ Viewpoint on Global Market Scenario

The global market for diabetes devices is estimated to grow at a rapid pace by 2031. Diabetes devices are used to diagnose and monitor blood glucose level in a diabetic patient’s body. Increase in demand for minimally invasive devices has prompted companies to launch patient-convenient blood glucose monitoring devices. Surge in patient pool suffering from diabetes has led to rise in the demand for diabetes lancet devices and diabetes care devices. The geriatric population is highly susceptible to diabetes, which has propelled the demand for diabetes tracker devices. Furthermore, initiatives taken by governments to spread awareness about diabetes devices have fueled the global diabetes care devices market size. Improvement in healthcare infrastructure and economic growth are also propelling the diabetes devices market demand. However, less awareness about the usage of devices in remote and underdeveloped regions, long registration processes, and reimbursement issues are likely to restrain the global market. Nevertheless, companies are focusing on minimizing the cost of diabetes tracker devices, which is likely to increase the demand for these devices.

Diabetes Devices Market

Diabetes Care Devises Market Introduction

Diabetes is a global issue affecting millions of people every year. In the last decade, type 1 diabetes has been one of the major healthcare concerns across the world. Countries such as the U.S., China, the U.K., and Germany have witnessed increasing rates of type 1 diabetes incidence. Type 1 diabetes is a form of autoimmune disease that occurs in children and adults, in which the pancreas stops producing insulin. The surge in the incidence of type 1 diabetes among children is one of the major healthcare concerns. According to IDF, in 2015, Europe had 140,000 children (0-14 years) with type-1 diabetes, and 21,600 new cases are diagnosed every year. Type-1 diabetes patients primarily use insulin pens or insulin pumps. Insulin pumps are more expensive than other insulin delivery devices. However, according to diabetes device market trends, the adoption of insulin pumps is increasing at a steady pace in developing and developed countries.

Request a sample to get extensive insights into the Diabetes Devices Market

Impact of COVID-19 on the Diabetes Care Devices Market

The COVID-19 pandemic has had a negative effect on the global market. The pandemic resulted in stock market turbulence, stringent border controls, and countrywide lockdowns, all taking their toll on various sectors. The pandemic has significantly strained hospital resources, including medical equipment and healthcare professionals. The supply chain of diabetes devices has been hampered, which has negatively affected the diabetes device market. However, diabetes is a chronic disease, and governments have sought to maintain a regular supply of diabetes devices. A large population worked from home during the lockdown, and numerous patients used remote monitoring devices for diabetics. People were more focused on their diet to control diabetes naturally by regulating their food. These factors hampered the market for diabetes devices.

Availability of Diabetes Tracker Devices with Advanced Sensors Fueling Glucose Monitoring Devices Segment

In terms of product type, the global diabetes devices market has been classified into glucose monitoring devices, insulin delivery devices, diabetes monitoring software, and artificial pancreas systems. The glucose monitoring devices segment has been segregated into self-monitoring blood glucose meters, blood glucose testing strips, lancets, and continuous glucose monitoring meters. The insulin delivery devices market segment has been split into insulin syringes, insulin pens, and insulin pumps. The glucose monitoring devices segment dominated the global market for diabetes care devices in 2021. The trend is projected to continue during the forecast period. The wide availability of diabetes tracker devices with advanced sensors for the detection of blood sugar levels is a major driver of the segment. Moreover, the usage of wireless technology in continuous glucose monitoring (CGM) for transmitting glucose readings collected from the interstitial fluid between the patient’s skin cells has become an important tool for diabetes monitoring devices.

Request a custom report on Diabetes Devices Market

High Prevalence of Type 2 and 1 Diabetes Bolstering Hospital Pharmacies Segment

Based on distribution channels, the global diabetes care devices market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and diabetes clinics/centers. Hospital pharmacies is projected to be a highly attractive segment during the forecast period. A high prevalence of type 2 and 1 diabetes is anticipated to increase hospital visits. Furthermore, the prevalence of diabetes among hospitalized patients is a major factor that drives the demand for diabetes devices at hospital pharmacies. The hospital pharmacies segment is likely to dominate the diabetes devices market during the forecast period. An increase in investment in R&D and a promising pipeline of artificial pancreas systems are anticipated to fuel the hospital pharmacies segment.

Regional Outlook of the Global Diabetes Devices Industry

North America accounted for a major share of the global diabetes devices market in 2021. This is ascribed to the large diabetes population, higher awareness, significant healthcare spending in the overall national budget, early availability of advanced technologies, and higher penetration of healthcare services across the country. The U.S. is a major market for diabetes devices in North America. Factors such as the aging population, highly structured healthcare industry, and availability of well-defined reimbursement policies from public and private health insurance firms augment the diabetes care devices market in the U.S. A report published in 2022 stated that the U.S. accounted for 37.3 million people who have diabetes, which is 11.3% of the population of the country. Around 28.7 million people have been diagnosed with diabetes. Among these, 8.5 million people who have diabetes have not been diagnosed and do not know they have it. Diabetes is the leading cause of kidney failure, blindness, and amputations in the U.S.

The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period due to the rise in the prevalence of infectious diseases. An increase in the geriatric population, a surge in healthcare expenditure, and a rise in patient awareness about diabetes devices are fueling the market in the region. Countries such as China and India are expected to dominate the diabetes devices business in the region in the next few years. Asia Pacific is a relatively untapped market than developed regions. Hence, the region presents better growth opportunities in this market. China and India are the most populous countries in the world and have the maximum number of diabetes patients. According to the International Diabetes Federation 2017, China has the largest number of people with diabetes aged between 20 and 79 years.

Analysis of Key Players in the Global Diabetes Devices Market

The diabetes devices market report includes vital information about leading players in the global market. Companies are adopting product launches, divestiture, mergers & acquisitions, and partnership strategies to enhance their market share. Medtronic, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Tandem Diabetes Care, Inc., Abbott Laboratories, Cellnovo, Insulet Corporation, LifeScan, Inc., and Owen Mumford Ltd. are the prominent players operating in the global market.

Key Developments in the Global Market

  • In May 2022, Labcorp announced the launch of the at-home collection device Labcorp OnDemand, which measures hemoglobin A1c (HbA1c) from a small blood sample. The Labcorp OnDemand Diabetes Risk test uses dried blood technology to provide average blood sugar levels over time. With a prick of the finger and a few drops of blood, consumers can proactively monitor their health status on a regular basis from the comfort of their homes.
  • In January 2020, Tandem Diabetes Care, Inc. launched a slim X2 insulin pump with Control-IQ technology. The device comes with an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL).
  • In May 2019, Roche Diabetes Care India launched Accu-Chek, a diabetes blood monitoring device, and the ‘mySugr’ app aimed at the betterment of people with diabetes

Each of these players has been profiled in the diabetes care devices market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Diabetes Devices Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 50.5 Bn

Market Forecast Value in 2031

More than US$ 90.2 Bn

Growth Rate (CAGR) for 2022–2031

6.0%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • The section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Glucose Monitoring Devices
      • Self-monitoring Blood Glucose Meters
      • Blood Glucose Testing Strips
      • Lancets
      • Continuous Glucose Monitoring Meters
    • Insulin Delivery Devices
      • Insulin Syringes
      • Insulin Pens
      • Insulin Pumps
    • Diabetes Management Software
    • Artificial Pancreas System
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Diabetes Clinics/Centers

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Medtronic
  • Novo Nordisk A/S
  • Sanofi
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson, and Company
  • Tandem Diabetes Care, Inc.
  • Abbott Laboratories
  • Cellnovo
  • Insulet Corporation
  • LifeScan, Inc.
  • Owen Mumford Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global diabetes devices market in 2021?

The global market was valued at US$ 50.5 Bn in 2021

How big will be the global diabetes care devices market by 2031?

The global market is projected to reach more than US$ 90.2 Bn by 2031

What will be the CAGR of the global diabetes devices business during the forecast period (2022–2031)?

The global market is anticipated to grow at a CAGR of 6.0% from 2022 to 2031

Which are the prominent trends that affect market growth?

Rise in prevalence of diabetes and increase in adoption of insulin pumps among type 1 diabetes patients are driving the global market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for a major share of the global market for diabetes devices during the forecast period

Who are the prominent players in the global diabetes devices industry?

Medtronic, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Tandem Diabetes Care, Inc., Abbott Laboratories, Cellnovo, Insulet Corporation, LifeScan, Inc., and Owen Mumford Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Diabetes Devices Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Diabetes Devices Market Analysis and Forecast, 2017–2031

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Technological Advancements

        5.2. Value Chain Analysis

        5.3. Estimated Number of People with Diabetes Worldwide and Per Region (Age 20-79 years)

        5.4. Emerging Technologies in Diabetes Management

        5.5. COVID-19 Impact Analysis

    6. Global Diabetes Devices Market Analysis and Forecast, by Product Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product Type, 2017–2031

            6.3.1. Glucose Monitoring Devices

                6.3.1.1. Self-monitoring Blood Glucose Meters

                6.3.1.2. Blood Glucose Testing Strips

                6.3.1.3. Lancets

                6.3.1.4. Continuous Glucose Monitoring Meters

            6.3.2. Insulin Delivery Devices

                6.3.2.1. Insulin Syringes

                6.3.2.2. Insulin Pens

                6.3.2.3. Insulin Pumps

            6.3.3. Diabetes Management Software

            6.3.4. Artificial Pancreas System

        6.4. Market Attractiveness Analysis, by Product Type

    7. Global Diabetes Devices Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Distribution Channel, 2017–2031

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

            7.3.4. Diabetes Clinics/Centers

        7.4. Market Attractiveness Analysis, by Distribution Channel

    8. Global Diabetes Devices Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Diabetes Devices Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Product Type, 2017–2031

            9.2.1. Glucose Monitoring Devices

                9.2.1.1. Self-monitoring Blood Glucose Meters

                9.2.1.2. Blood Glucose Testing Strips

                9.2.1.3. Lancets

                9.2.1.4. Continuous Glucose Monitoring Meters

            9.2.2. Insulin Delivery Devices

                9.2.2.1. Insulin Syringes

                9.2.2.2. Insulin Pens

                9.2.2.3. Insulin Pumps

            9.2.3. Diabetes Management Software

            9.2.4. Artificial Pancreas System

        9.3. Market Value Forecast, by Distribution Channel, 2017–2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

            9.3.4. Diabetes Clinics/Centers

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Product Type

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Diabetes Devices Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product Type, 2017–2031

            10.2.1. Glucose Monitoring Devices

                10.2.1.1. Self-monitoring Blood Glucose Meters

                10.2.1.2. Blood Glucose Testing Strips

                10.2.1.3. Lancets

                10.2.1.4. Continuous Glucose Monitoring Meters

            10.2.2. Insulin Delivery Devices

                10.2.2.1. Insulin Syringes

                10.2.2.2. Insulin Pens

                10.2.2.3. Insulin Pumps

            10.2.3. Diabetes Management Software

            10.2.4. Artificial Pancreas System

        10.3. Market Value Forecast, by Distribution Channel, 2017–2031

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

            10.3.4. Diabetes Clinics/Centers

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Product Type

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Diabetes Devices Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product Type, 2017–2031

            11.2.1. Glucose Monitoring Devices

                11.2.1.1. Self-monitoring Blood Glucose Meters

                11.2.1.2. Blood Glucose Testing Strips

                11.2.1.3. Lancets

                11.2.1.4. Continuous Glucose Monitoring Meters

            11.2.2. Insulin Delivery Devices

                11.2.2.1. Insulin Syringes

                11.2.2.2. Insulin Pens

                11.2.2.3. Insulin Pumps

            11.2.3. Diabetes Management Software

            11.2.4. Artificial Pancreas System

        11.3. Market Value Forecast, by Distribution Channel, 2017–2031

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

            11.3.4. Diabetes Clinics/Centers

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Product Type

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Diabetes Devices Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product Type, 2017–2031

            12.2.1. Glucose Monitoring Devices

                12.2.1.1. Self-monitoring Blood Glucose Meters

                12.2.1.2. Blood Glucose Testing Strips

                12.2.1.3. Lancets

                12.2.1.4. Continuous Glucose Monitoring Meters

            12.2.2. Insulin Delivery Devices

                12.2.2.1. Insulin Syringes

                12.2.2.2. Insulin Pens

                12.2.2.3. Insulin Pumps

            12.2.3. Diabetes Management Software

            12.2.4. Artificial Pancreas System

        12.3. Market Value Forecast, by Distribution Channel, 2017–2031

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

            12.3.4. Diabetes Clinics/Centers

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Product Type

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Diabetes Devices Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product Type, 2017–2031

            13.2.1. Glucose Monitoring Devices

                13.2.1.1. Self-monitoring Blood Glucose Meters

                13.2.1.2. Blood Glucose Testing Strips

                13.2.1.3. Lancets

                13.2.1.4. Continuous Glucose Monitoring Meters

            13.2.2. Insulin Delivery Devices

                13.2.2.1. Insulin Syringes

                13.2.2.2. Insulin Pens

                13.2.2.3. Insulin Pumps

            13.2.3. Diabetes Management Software

            13.2.4. Artificial Pancreas System

        13.3. Market Value Forecast, by Distribution Channel, 2017–2031

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

            13.3.4. Diabetes Clinics/Centers

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Product Type

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company, 2021

        14.3. Company Profiles

            14.3.1. Medtronic

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. SWOT Analysis

                14.3.1.4. Strategic Overview

            14.3.2. Novo Nordisk A/S

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. SWOT Analysis

                14.3.2.4. Strategic Overview

            14.3.3. Sanofi

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. SWOT Analysis

                14.3.3.4. Strategic Overview

            14.3.4. Eli Lilly and Company

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. SWOT Analysis

                14.3.4.4. Strategic Overview

            14.3.5. F. Hoffmann-La Roche Ltd.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. SWOT Analysis

                14.3.5.4. Strategic Overview

            14.3.6. Becton Dickinson and Company

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. SWOT Analysis

                14.3.6.4. Strategic Overview

            14.3.7. Tandem Diabetes Care, Inc.

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. SWOT Analysis

                14.3.7.4. Strategic Overview

            14.3.8. Abbott Laboratories

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. SWOT Analysis

                14.3.8.4. Strategic Overview

            14.3.9. Cellnovo

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. SWOT Analysis

                14.3.9.4. Strategic Overview

            14.3.10. Insulet Corporation

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. SWOT Analysis

                14.3.10.4. Strategic Overview

            14.3.11. LifeScan, Inc.

                14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.11.2. Product Portfolio

                14.3.11.3. SWOT Analysis

                14.3.11.4. Strategic Overview

            14.3.12. Owen Mumford Ltd.

                14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.12.2. Product Portfolio

                14.3.12.3. SWOT Analysis

                14.3.12.4. Strategic Overview

    List of Tables

    Table 01: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product type, 2017–2031

    Table 02: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Glucose Monitoring Devices 2017–2031

    Table 03: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Insulin Delivery Devices, 2017–2031

    Table 04: Global Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 05: Global Insulin Delivery Devices Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 08: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Glucose Monitoring Devices 2017–2031

    Table 09: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Insulin Delivery Devices, 2017–2031

    Table 10: North America Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 11: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 13: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Glucose Monitoring Devices, 2017–2031

    Table 14: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type – Insulin Delivery Devices, 2017–2031

    Table 15: Europe Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 18: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017–2031

    Table 19: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017–2031

    Table 20: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 23: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017–2031

    Table 24: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017–2031

    Table 25: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 26: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

    Table 28: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Glucose Monitoring Devices, 2017–2031

    Table 29: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Insulin Delivery Devices, 2017–2031

    Table 30: Middle East & Africa Diabetes Devices Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Diabetes Devices Market, by Product, Market Size (US$ Mn), 2021 (A)

    Figure 02: Global Diabetes Devices Market, by Distribution Channel, Market Share, 2021 (A)

    Figure 03: Global Diabetes Devices Market Size (US$ Mn) Forecast, 2017–2031

    Figure 04: Company Revenue Share (1)

    Figure 05: Company Revenue Share (2)

    Figure 06: Estimated Number of People with Diabetes Worldwide and Per Region (Age 20-79 years)

    Figure 07: Global Diabetes Devices Market Value Share, by Product Type, 2021 and 2025

    Figure 08: Global Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022–2031

    Figure 09: Global Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 10: Global America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2021 and 2031

    Figure 11: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glucose Monitoring Devices, 2017–2031

    Figure 12: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Insulin Delivery Devices, 2017–2031

    Figure 13: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetes Monitoring Software, 2017–2031

    Figure 14: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Pancreas System, 2017–2031

    Figure 15: Global Diabetes Devices Market Value Share, by Distribution Channel, 2021 and 2025

    Figure16: Global Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 17: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2031

    Figure 18: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031

    Figure 19: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2031

    Figure 20: Global Diabetes Devices Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetes Clinics/ Centers, 2017–2031

    Figure 21: Global Diabetes Device Market Scenario, by Country (1/1)

    Figure 22: Global Diabetes Devices Market Value Share Analysis, by Region, 2021 and 2025

    Figure 23: Global Diabetes Devices Market Attractiveness Analysis, by Region, 2022–2031

    Figure 24: North America Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 25: North America Diabetes Devices Market Attractiveness Analysis, by Country, 2022–2031

    Figure 26: North America Diabetes Devices Market Value Share Analysis, by Country, 2021 and 2031

    Figure 27: North America Diabetes Devices Market Value Share, by Product Type, 2021 and 2031

    Figure 28: North America Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022–2031

    Figure 29: North America Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 30: North America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2021 and 2031

    Figure 31: North America Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Fig 32: North America Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

    Figure 34: Europe Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 35: Europe Diabetes Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 36: Europe Diabetes Devices Market Value Share, by Product Type, 2021 and 2031

    Figure 37: Europe Diabetes Devices Market Attractiveness Analysis, by Product Type, 2017–2031

    Figure 38: Europe Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 39: Europe Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017–2031

    Figure 40: Europe Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 41: Europe Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Diabetes Devices Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2017–2031

    Figure 43: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 44: Asia Pacific Diabetes Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 45: Asia Pacific Diabetes Devices Market Value Share Analysis, by Product Type, 2021 and 2031

    Figure 46: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022–2031

    Figure 47: Asia Pacific Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 48: Asia Pacific Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017–2031

    Figure 48: Asia Pacific Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017–2031

    Figure 49: Asia Pacific Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 50: Asia Pacific Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Diabetes Devices Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2017–2031

    Figure 52: Latin America Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 53: Latin America Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 54: Latin America Market Value Share Analysis, by Product Type, 2021 and 2031

    Figure 55: Latin America Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022–2031

    Figure 56: Latin America Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 57: Latin America Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017–2031

    Figure 58: Latin America Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 59: Latin America Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Diabetes Devices Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast 2017–2031

    Figure 61: Middle East & Africa Diabetes Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 62: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 63: Middle East & Africa Market Value Share Analysis, by Product Type, 2022–2031

    Figure 64: Middle Diabetes Devices Market Attractiveness Analysis, by Product Type, 2022–2031

    Figure 65: Middle East & Africa Diabetes Devices Market Value Share, by Glucose Monitoring Devices, 2021 and 2031

    Figure 66: Middle East & Africa Diabetes Devices Market Value Share, by Insulin Delivery Devices, 2017–2031

    Figure 67: Middle East & Africa Diabetes Devices Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 68: Middle East & Africa Diabetes Devices Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 69: Medtronic, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 70: Medtronic, R&D Intensity and Sales & Marketing Intensity (%) – Company Level or Segment Level, 2017–2021

    Figure 71: Medtronic, Breakdown of Net Sales, by Region 2017

    Figure 72: Medtronic, Breakdown of Net Sales, by Business Segments, 2017

    Figure 73: Novo Nordisk A/S, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 74: Novo Nordisk A/S, R&D Intensity and Sales & Marketing Intensity (%), 2017–2021

    Figure 75: Novo Nordisk A/S, Breakdown of Net Sales, by Region 2021

    Figure 76: Novo Nordisk A/S, Breakdown of Net Sales, by Business Segments, 2021

    Figure 77: Sanofi, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 78: Sanofi, R&D Intensity and Sales & Marketing Intensity (US$ Bn), 2017–2021

    Figure 79: Sanofi, Breakdown of Net Sales, by Region 2021

    Figure 80: Sanofi, Breakdown of Net Sales, by Business Segments, 2021

    Figure 81: Eli Lilly and Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 82: Eli Lilly and Company, R&D Intensity and Sales & Marketing Intensity – Company Level, 2017–2021

    Figure 83: Eli Lilly and Company, Breakdown of Net Sales, by Region 2017

    Figure 84: Eli Lilly and Company, Breakdown of Net Sales, by Endocrinology Segment, 2021

    Figure 85: F. Hoffmann-La Roche Ltd., Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 86: F. Hoffmann-La Roche Ltd., R&D Intensity (US$ Bn), 2017–2021

    Figure 87: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales of Diabetes Care Business Area, by Region 2021

    Figure 88: F. Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Diagnostic Division, 2021

    Figure 89: Becton, Dickinson and Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 90: Becton, Dickinson and Company, R&D Expense (US$ Mn), 2017–2021

    Figure 91: Becton, Dickinson and Company, Breakdown of Net Sales, by Region 2021

    Figure 92: Becton, Dickinson and Company, Breakdown of Net Sales, by BD Medical Business segment, 2021

    Figure 93: Tandem Diabetes Care, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2017–2021

    Figure 94: Tandem Diabetes Care, Inc., R&D Expense (US$ Mn), 2017–2021

    Figure 95: Abbott Laboratories, Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 96: Abbott Laboratories, R&D Intensity and Sales & Marketing Intensity – Company Level, 2017–2021

    Figure 97: Abbott Laboratories, Breakdown of Net Sales, by Region 2021

    Figure 98: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2021

    Figure 99: Cellnovo, Revenue (US$ Mn) & Y-o-Y Growth (%), 2017–2021

    Figure 100: Insulet Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2017–2021

    Figure 101: Insulet Corporation, R&D Intensity and Sales & Marketing Intensity (US$ Mn) – Company Level, 2017–2021

    Figure 102: Insulet Corporation, Breakdown of Net Sales, by Region, 2021

    Figure 103: Insulet Corporation, Breakdown of Net Sales, by Business Segments 2021

    Figure 104: LifeScan, Inc., Concerned Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2017–2021

    Figure 105: LifeScan, Inc., R&D Intensity and Sales & Marketing Intensity – Company Level, 2017–2021

    Figure 106: LifeScan, Inc., Breakdown of Net Sales, by Region (Company Level), 2021

    Figure 107: LifeScan, Inc., Breakdown of Net Sales, (By Business And Business Segment Level), 2021

Copyright © Transparency Market Research, Inc. All Rights reserved